ASP.. Acerus Pharmaceuticals

Acerus Reports Third Quarter 2022 Financial Results

Acerus Reports Third Quarter 2022 Financial Results

TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) --  Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and nine-month period ended September 30, 2022. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”).

Recent Highlights

  • Total Natesto® prescriptions in the US rose 69% year-over-year in the third quarter of 2022 and were up approximately 10% sequentially over the fiscal 2022 second quarter
  • Natesto® returns to the Canadian market with shipments resuming late in the third quarter
  • The Company continues its preparations for the re-launch of Noctiva™ in the US
  • Additional non-dilutive financing of US$10.0 million from First Generation Capital during the third quarter to support the Company’s operations
  • Strategic review launched in the quarter supported by Ernst & Young Orenda Corporate Finance
  • Naveed Manzoor appointed as interim Chief Financial Officer effective November 15, 2022

“I’m pleased to report that Acerus continues to show positive momentum this quarter,” said Edward Gudaitis, President and Chief Executive Officer of Acerus Pharmaceuticals. “Revenue rose significantly when compared to the prior year quarter. While the total market for testosterone therapy grew by 6% in the third quarter of 2022 compared to the prior year period, total Natesto® prescriptions in the US climbed 69% year-over-year. In addition, prescriptions in the third quarter grew by 10% over the second quarter, driven by our highly-effective sales staff as well as general growing interest in the efficacy of our products. In fact, Natesto® was the fastest-growing branded testosterone therapy in the market for the last two quarters.”

“At the same time, we recognize that ongoing access to capital to allow us to continue to grow our business remains a challenge in the current economic environment. As a result, a committee of independent directors of our Board has been formed to undertake a strategic review of our operations. We have also engaged Ernst & Young Orenda Corporate Finance to act as financial advisors during this review process. We expect to report on the results of that review later in the fourth quarter.”

Summary of Results for the Three Months Ended September 30, 2022 (Q3-2022) compared to the Three Months Ended September 30, 2021 (Q3-2021), unless otherwise noted

Total revenue for the quarter was $0.77 million compared to $0.59 million in the prior-year period, reflecting the impact of prescription growth in the US, partially offset by increased rebates to carriers and pharmacy benefit managers.

Gross profit for Q3-2022 was $0.6 million compared to $0.1 million in the Q3-2021. The Q3-2021 cost of goods sold included a charge of $0.3 million to write off a manufacturing batch of Natesto® produced by our contract manufacturer that did not meet manufacturing specifications.

Research and development ("R&D") expense rose by $0.6 million, to $1.9 million, in Q3-2022 from $1.3 million in Q3-2021, reflecting increased expense for NATESTO® clinical trials in the US. As previously noted in prior earnings releases, this higher level of R&D is expected to continue for the next few quarters, after which the clinical trials should be complete. In addition, current quarter R&D included $0.3 million of expense to return Noctiva™ to active production.

Second quarter selling, general and administrative expense (“SG&A”) declined by $0.7 million, to $4.3 million, from $5.0 million in Q2-2021. Approximately $0.7 million of the decline reflects the reversal of bonuses previously accrued for 2021 and 2022 that the Company determined will no longer be paid. In addition, expenses incurred in our US sales and marketing operations were lower than in the prior year. Offsetting these declines was a charge of $0.7 million to business development expenses for costs associated with an unsuccessful debt financing facility application.

Included in Q3-2022 other income and expenses was a gain of $3.0 million related to the restructuring of the promissory note due to former shareholders of Serenity. As repayment of this note is now tied to the reintroduction of Noctiva™ to the US market, much of the note was de-recognized as a liability under IFRS.

EBITDA1 was a loss of $5.6 million in the third quarter of 2022 compared to a loss of $3.9 million in the prior-year period; Adjusted EBITDA1 was a loss of $5.5 million in 2022 compared to a loss of $5.9 million in 2021.

The Company incurred a net loss of $4.2 million, or $(0.54) per share, for Q3-2022 compared to a loss of $4.9 million, or $(0.64) per share, in Q3-2021.

Cash as of September 30, 2022 was $3.0 million compared with $2.2 million as of December 31, 2021, reflecting $27.9 million of advances under a secured grid promissory note with First Generation Capital Inc., a company affiliated with the Chairman of the Board of Directors of Acerus (“First Generation”), offset by (i) $6.5 million to settle the prior senior secured loan facility with SWK, (ii) $18.6 million of cash used in operations; and (iii) $1.8 million for the acquisition of Serenity.

Given the current economic environment and the associated challenges in raising capital, the Company announced in the quarter that it had engaged a committee of independent directors to undertake a strategic review of the Company. Ernst & Young Orenda Corporate Finance has been retained as financial advisors to assist in this process. The Company’s capital requirements over the next two years will be informed by the outcome of this strategic review process and may differ from the $45-50 million capital requirement that was previously noted in prior press releases.

COMPANY UPDATE AND OUTLOOK

NoctivaTM

Acerus, along with its contract manufacturer, continue to execute on the resumption of manufacturing of Noctiva™ for the US market, where it already has FDA approval. The rollout strategy for Noctiva™ – including all related marketing, distribution and production – has slowed due to working capital constraints and will be dependent on the result of the strategic review process.

Natesto®

The Company has been successful growing Natesto® as prescriptions rose 69% year-over-year in the third quarter. 

The Canadian reintroduction of Natesto® occurred late in the third quarter of 2022 and the Company has begun recognizing revenues as prescriptions resume.

avanafil

Acerus has been working with Petros Pharmaceuticals, the licensor of avanafil to Acerus, and Sanofi to update the regulatory dossier for resubmission to Health Canada. As part of the Strategic Review Process, the company is evaluating options for avanafil that may affect the timing and/or probability of a resubmission to Health Canada.

Interim CFO Appointment

Today the Company appointed Naveed Manzoor as Interim Chief Financial officer. Mr. Manzoor is managing director at FAAN Advisors, a consulting practice providing, among other things, Interim CFO Services. Mr. Manzoor is a Chartered Professional Accountant

About Acerus

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the fields of Urology and Men’s Health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit and follow us on Twitter and LinkedIn.

1 Non-IFRS Financial Measures - EBITDA and Adjusted EBITDA

The non-IFRS measures included in this press release are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers. When used, these measures are defined in such terms as to allow the reconciliation to the closest IFRS measure. These measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from our perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. Despite the importance of these measures to management in goal setting and performance measurement, we stress that these are non-IFRS measures that may have limits in their usefulness to investors.

We use non-IFRS measures, such as EBITDA and Adjusted EBITDA to provide investors with a supplemental measure of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures. We also believe that securities analysts, investors and other interested parties frequently use non-IFRS measures in the valuation of issuers. We also use non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets, and to assess our ability to meet our future debt service, capital expenditure and working capital requirements.

The definition and reconciliation of EBITDA and Adjusted EBITDA used and presented by the Company to the most directly comparable IFRS measures follows below:

EBITDA is defined as net (loss)/income adjusted for income tax, depreciation of property and equipment, amortization of intangible assets, interest on long-term debt and other financing costs, interest income, licensing revenue and changes in fair values of derivative financial instruments. Management uses EBITDA to assess the Company’s operating performance.

Adjusted EBITDA is defined as EBITDA adjusted for, as applicable, royalty expenses associated with triggering events, milestones, share based compensation, impairment of intangible asset, foreign exchange (gain)/loss, charges related to product recall and gain on extinguishment of payables. We use Adjusted EBITDA as a key metric in assessing our business performance when we compare results to budgets, forecasts and prior years. Management believes Adjusted EBITDA is an alternative measure of cash flow generation than, for example, cash flow from operations, particularly because it removes cash flow fluctuations caused by extraordinary changes in working capital. A reconciliation of net (loss)/income to EBITDA (and Adjusted EBITDA) is set out below.





   For the three months ended September 30, For the nine months ended September 30, 
    2022  2021   2022  2021  
Net loss $(4,173)$(4,898) $(19,058)$(24,794) 
Adjustments:       
 Amortization of intangible assets  10  37   30  112  
 Depreciation of property and equipment 39  36   117  479  
 Depreciation of right of use asset  8  7   23  10  
 Interest expense and other financing costs* 1,529  1,007   4,257  1,707  
 Interest income  (9) 2   (12) (5) 
 Change in fair value of derivative (14) (53)  (45) (41) 
 (Gain) loss on modification of debt (2,958) -   (2,958) 64  
EBITDA $(5,568)$(3,862) $(17,646)$(22,468) 
         
Termination Fees  -  -   -  6,254  
Litigation settlement proceeds  -  (2,328)  -  (2,328) 
Share based compensation  96  333   513  800  
Foreign exchange gain  (63) (31)  (85) (71) 
Gain from sale of property and equipment -  -   -  56  
Adjusted EBITDA $(5,535)$(5,888) $(17,218)$(17,757) 
         

Notice Regarding Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the commercial performance of NATESTO® and Noctiva globally and in the U.S., and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 14, 2022 which is available at Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Company Contact

Naveed Manzoor

Chief Financial Officer



 

Acerus Pharmaceuticals Corporation    
Condensed Interim Consolidated Statements of Financial Position    
As at September 30, 2022 and December 31, 2021    
Unaudited      
(expressed in thousands of U.S. dollars)     
        
     September 30, 2022December 31, 2021 
        
ASSETS      
        
Current assets      
 Cash   $3,020 $2,159  
 Trade and other receivables    1,131  422  
 Inventory    5,120  4,605  
 Prepaid and other assets    1,145  1,463  
Total current assets    10,416  8,649  
        
Property and equipment    338  365  
Right of use asset    279  302  
Intangible assets    36,637  336  
Total assets   $47,670 $9,652  
        
LIABILITIES AND SHAREHOLDERS' DEFICIT    
        
Current liabilities      
 Accounts payable and accrued liabilities  $8,559 $7,448  
 Provisions    2,118  -  
 Deferred cash consideration    750  -  
 Termination fee payable    4,002  2,456  
 Current portion of long-term debt   -  2,153  
 Current portion of lease liability   23  16  
Total current liabilities    15,452  12,073  
        
Termination fee payable    -  2,101  
Lease liability    286  300  
Long-term debt    43,872  21,137  
Promissory note    1,950  -  
Derivative financial instrument    5  55  
Total liabilities    61,565  35,666  
        
Shareholders' deficit      
 Share capital   $198,346 $198,163  
 Contributed surplus    49,072  18,078  
 Accumulated other comprehensive loss   (13,949) (13,949) 
 Deficit    (247,364) (228,306) 
Total shareholders' deficit    (13,895) (26,014) 
Total liabilities & shareholders' deficit  $47,670 $9,652  
        



Acerus Pharmaceuticals Corporation         
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss     
For the three and nine months ended September 30, 2022 and 2021       
Unaudited          
(expressed in thousands of U.S. dollars, except per share and share data)       
    For the three months ended September 30, For the nine months ended September 30, 
     2022   2021   2022   2021  
            
Revenue          
Product revenue  $770  $587  $2,300  $1,383  
Termination Fees   -   -   -   (6,254) 
     770 - 587 - 2,300 - (4,871) 
Cost of goods sold 202   489   934   725  
Gross margin (loss)   568   98   1,366   (5,596) 
            
Expenses          
 Research and development   1,936   1,353   5,460   3,254  
 Selling, general and administrative   4,320   5,046   13,807   16,618  
Total operating expenses   6,256   6,399   19,267   19,872  
Operating loss   (5,688)  (6,301)  (17,901)  (25,468) 
            
Other expenses (income)          
 Interest on long-term debt and other financing costs   1,529   1,007   4,257   1,707  
 Litigation settlement proceeds   -   (2,328)  -   (2,328) 
 Interest income   (9)  2   (12)  (5) 
 Foreign exchange gain   (63)  (31)  (85)  (71) 
 Change in fair value of derivative financial instruments   (14)  (53)  (45)  (41) 
 (Gain) loss on debt modification   (2,958)  -   (2,958)  64  
Total other expenses (income)   (1,515)  (1,403)  1,157   (674) 
Loss for the year before income taxes   (4,173)  (4,898)  (19,058)  (24,794) 
            
Income tax expense   -   -   -   -  
Net loss and comprehensive loss for the period $(4,173) $(4,898) $(19,058) $(24,794) 
            
Loss per common share          
 Basic and diluted net loss per common share $(0.54) $(0.64) $(2.47) $(3.23) 
            
Weighted average common shares outstanding         
 Basic and diluted   7,702,297   7,687,940   7,702,297   7,687,940  
            

 



EN
15/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Acerus Pharmaceuticals

 PRESS RELEASE

Acerus Update

Acerus Update TORONTO, July 10, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company”) announces that, in connection with its creditor protection proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) and its previously announced sale and investment solicitation process (the “SISP”), the Company completed the previously announced transactions (the “Transaction”) with First Generation Capital Inc. (“First Generation”) as successful bidder under the SISP. The Transaction was approved by the Ontario Superior Court of Justice (Commercial List) (the “Court...

 PRESS RELEASE

Acerus Update

Acerus Update TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- As announced on January 26, 2023, Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) and its subsidiaries were granted creditor protection pursuant to an order (the “Initial Order”) granted by the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”). Pursuant to the Initial Order, Ernst & Young Inc. was appointed as monitor of the Company (in such capacity, the “Monitor”). As announced on March 14, 2023, the Court granted an order (the “SISP Ord...

 PRESS RELEASE

Acerus Announces Commencement of Court-Approved Sale and Investment So...

Acerus Announces Commencement of Court-Approved Sale and Investment Solicitation Process TORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- On January 26, 2023, Acerus Pharmaceuticals Corporation and certain of its subsidiaries (collectively, “Acerus”) were granted protection pursuant to an order (the “Initial Order”) issued under the Companies’ Creditors Arrangement Act (the “CCAA Proceedings”) by the Ontario Superior Court of Justice (the “Canadian Court”). Ernst & Young Inc. was appointed Monitor of Acerus (in such capacity, the “Monitor”). On February 3, 2023, the Initial Order was amended a...

 PRESS RELEASE

Acerus Files For CCAA Protection

Acerus Files For CCAA Protection TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus Biopharma Inc., Acerus Labs Inc. and Acerus Pharmaceuticals USA, LLC (collectively, the “Acerus Group”), have received an order for creditor protection (the “Initial Order”) from the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”). As previously disclosed on September 21, 2022, Acerus unde...

 PRESS RELEASE

Acerus Announces Resignation of Director

Acerus Announces Resignation of Director TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board of directors of the Company, effective immediately. About Acerus Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. Acerus’ shares trade on TSX under the symbol AS...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch